Floatz logo

Tilt-123

Lung Cancer

TILT Biotherapeutics Ltd.gene_therapyPhase 1Active
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
65/ 100

Competitive context

303 Active assets in the Lung Cancer cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
University of Vermont
Phase 4BB
Carboplatin
SystImmune Inc.
Phase 4BB
Nivolumab
University of Chicago
Phase 4BB
ETOPOSIDE
SystImmune Inc.
Phase 3BB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BB

View all 50 →

Same molecule, other indications

Tilt-123 is also rated in:

ovarian carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
fallopian tube carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
primary peritoneal carcinomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →